ArticlePediatric rheumatology online journal2025
Predictors of relapse after withdrawing biotherapies in children with inactive juvenile idiopathic arthritis: a retrospective cohort study of the JIR cohort.
Article in Pediatric rheumatology online journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn patients with juvenile idiopathic arthritis (JIA), the approach to discontinuing biological treatments after a period of remission remains exploratory. We aimed to identify one or more predictors of relapse after the discontinuation of biologic/targeted synthetic disease-modifying anti-rheumatic drugs.
methodsWe reviewed JIA patients followed in two French tertiary centers and included in the JIR cohort who had discontinued their biologic treatments from 2000 to 2023. Remission was defined according to the Wallace criteria. The primary outcome was relapse within 1 year after treatment withdrawal. Multivariate regression was used to analyze predictors of relapse.
resultsA total of 697 JIA patients received treatment in the two centers during the study period. We analyzed 130 instances of treatment discontinuation in 115 patients (16.5%) (70.8% girls [92/130], median age 5.29 years at diagnosis [interquartile range 2.3–10.4]). Patients discontinued biological treatments after a median of 2.58 years, and 56.2% (73/130) of patients experienced relapse within 1 year after treatment withdrawal. The psoriasis subgroup had the highest relapse rate (89.5% [17/19]) and the systemic subgroup the lowest (33.3% [7/21]). The probably of relapse was increased with antinuclear antibody positivity at diagnosis (p < 0.05) and reduced with longer duration of clinically inactive disease before treatment withdrawal.
conclusionRelapses are common after discontinuing biologic therapies in JIA, particularly in patients with antinuclear antibody positivity and psoriatic arthritis and those who stop treatment shortly after reaching inactive disease status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.